Evommune, Inc. (EVMN) key performance indicators and operating metrics (2 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Phase 2b Dose-Ranging Clinical Trial Enrollment — Atopic Dermatitis | 120.00 | FY2026-Q1 |
| Phase 2b Dose-Ranging Clinical Trial Enrollment — Chronic Spontaneous Urticaria | 160.00 | FY2026-Q1 |
Back to EVMN overview · EVMN earnings · EVMN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.